764635-62-3

Usage

Uses

Used in Pharmaceutical Industry:
5,6,7,8-Tetrahydropyrido[3,4-b]pyrazine-7-carboxylic acid is used as a chemical compound for research and development purposes. Its unique structure and properties make it a promising candidate for further studies to explore its potential uses in the field of medicine.
Used in Medicinal Applications:
5,6,7,8-Tetrahydropyrido[3,4-b]pyrazine-7-carboxylic acid is used as a potential pharmaceutical agent due to its structure and properties. Further research is needed to determine its specific applications and efficacy in treating various medical conditions.

InChI:InChI=1/C8H9N3O2/c12-8(13)6-3-5-7(4-11-6)10-2-1-9-5/h1-2,6,11H,3-4H2,(H,12,13)

Upstream product

• 5910-89-4 2,3-dimethylpyrazine 
• 51043-75-5 2,3-bis(chloromethyl)pyrazine 
• 264623-82-7 ethyl 6-acetyl-7-ethoxycarbonyl-5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-7-carboxylate 

Downstream Products

• 264623-57-6 (+/-)-6-tert-butoxycarbonyl-5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-7-carboxylic acid 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids as HB-EGF shedding inhibitors

HB-EGF Shedding inhibitors have been expected to become effective medicines for skin diseases caused by the proliferation of keratinocytes. In order to discover novel HB-EGF shedding inhibitors and clarify their structure-activity relationships, 5,6,7,8-tetrahydronaphthylidine-based hydroxamic acid and 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids have been synthesized. Among the synthesized compounds, the ethoxyethoxy derivative 3o and the methoxypropoxy derivative 3p exhibited much more potent HB-EGF shedding inhibitory activity than CGS 27023A. The structural modification of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids enabled us to establish the following structure-activity relationships; the existences of the hydroxamic acid, the sulfonamide, and the phenyl moieties are crucial for a potent HB-EGF shedding inhibitory activity, and the stereochemistry of the alpha carbon of hydroxamic acid is also important. In addition, from the comparison of their HB-EGF shedding inhibitory activities with their MMPs inhibitory activities, we found that the S1′ pocket of the responsible enzyme for HB-EGF shedding is deep unlike that of MMP-1.